{"denoms":[{"counts":[{"groupId":"BG000","value":"330"}],"units":"Participants"}],"groups":[{"description":"Oral 25mg daily on Days 1-21 every 28 days","id":"BG000","title":"Lenalidomide 25mg (CC-5013)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.43","value":"63.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"136"}]}],"title":"> 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"194"}]}],"title":"≤ 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"137"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"193"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Asian/Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"309"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Hispanic"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"95"}]}],"title":"0 = Fully Active"},{"categories":[{"measurements":[{"groupId":"BG000","value":"178"}]}],"title":"1 = Restricted Activity"},{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}]}],"title":"2 = Ambulatory; not able to work"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"3 = Limited Self Care"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"4 = Completely Disabled"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Missing= Unspecified"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living activities of the patient and determine appropriate treatment and prognosis. 0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}]}